RecruitingNCT07164911

Predictive Factors of Response to Phase II Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction

Prédiction Des réponses du Patient Porteur d'Une Insuffisance Cardiaque à Fraction d'éjection altérée à Une Phase II de réadaptation Cardiaque


Sponsor

Centre Hospitalier de Corbie

Enrollment

62 participants

Start Date

Nov 25, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Exercise intolerance, measured as peak oxygen consumption (VO₂peak) during exercise in patients with heart failure with reduced ejection fraction (HFrEF). Change in VO₂peak (ΔVO₂peak), which serves as a prognostic marker for HFrEF engaged in exercise based cardiac rehabilitation program (ExCR). Responders to ExCR generally show improved cardiac function but some patients with HFrEF do not respond to ExCR. VO₂peak depends on three major components of oxygen transport: Pulmonary (lungs), circulatory (heart and vessels) and skeletal muscle (oxygen utilization) functions. These physiological responses to ExCR may be influenced by epigenetic regulation, specifically the expression of circulating microRNAs (c-miRNAs). Linking non-invasive measurements and epigenetic markers could 1) identify which component of the oxygen transport chain is most impaired and 2) allow personalized interventions to maximize VO₂peak improvements. The primary objective of this stidy is to assess the association between changes in VO₂peak during exercise training and circulating microRNA expression (miR-146a, miR-191, miR-23a, miR-140, miR-1, miR-21, miR-133a, miR-17-5p, miR-3200-3p). The secondary objective is to examine the relationship between pulmonary, cardiovascular, and neuromuscular adaptations to exercise and circulating microRNA expression.


Eligibility

Min Age: 40 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study looks for factors that can predict whether a structured exercise program (Phase II cardiac rehabilitation) will improve heart function in people with heart failure — specifically the type where the heart pumps poorly (reduced ejection fraction). The goal is to better personalize cardiac rehab programs. **You may be eligible if...** - You have heart failure with reduced ejection fraction (less than 40%) - Your symptoms are at least moderate (NYHA class II or higher) - Your condition has been stable for at least 6 weeks on optimized medication - You have been prescribed Phase II cardiac rehabilitation - Your BMI is between 20 and 30 - You are sedentary or physically active but untrained - You are covered by the French national health insurance **You may NOT be eligible if...** - You have conditions preventing regular physical activity - You have uncontrolled high blood pressure - You have significant lung disease such as COPD or emphysema - You have other significant cardiovascular conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Hospital center of Corbie

Corbie, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07164911


Related Trials